Bispecific antibodies offer advantages as therapeutic modalities, including precise targeting and increased efficacy. However, production in CHO cells can present challenges that affect COGs, such as incorrect antibody chain pairing. In this presentation we will describe bYlok®, a new technology that promotes highly efficient heavy-light chain dimerization, and show some case studies where bYlok® plus other tools in the Lonza GS® toolbox can be combined to improve bsAb expression
You may also be interested in:
Out-Licensed Expression Technologies
Bispecific Antibody
bYlok™ Bispecific Antibodies Technology
GS Gene Expression System®
GS piggyBac® Transposon System
GS Xceed® Gene Expression System
GSquad® Vectors
Mammalian Expression Technologies
Author(s):
Peter O'Callaghan, Ph.D.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
micro image
Technical/Service brief
GS Discovery® Transient Expression System
With GS Discovery® you can.... Speed up therapeutic candidate selection with...
Microdosing graphic
Webinar (on-demand)
Micro-dosing – Powder in Capsule Technology Pathway from Development to Commercialization
Micro-dosing can accelerate the journey of a drug product from early development through to...
Webinar (on-demand)
Solving Bispecific Antibody Heavy-Light Chain Mispairing with bYlok® Technology
Lonza’s bYlok® bispecific pairing technology is an innovative solution that drives correct...
AAV manufacturing
Webinar (on-demand)
Improving AAV Productivity and Packaging Efficiency for Transient and Producer Cell Lines Through...
Adeno-associated virus (AAV) gene therapy has shown immense promise in treating various genetic...
Video
How Does bYlok® Technology Work and How Can It Improve Bispecific Production?
Bispecific antibodies offer numerous potential clinical benefits, and the number of bispecifics in...
PBPK_scientist-in-lab-with-monitor
Webinar (on-demand)
PBPK Modeling for Identifying and Mitigating Absorption Risks in Early Drug Development
When coupled with in vitro measurements, PBPK modeling is effective in early development for 1)...
White paper
The Early Advantage for IND Success and Beyond
Many of the decisions made during the early days of building and compiling the manufacturing...
Immunogenicity Discovery Services
Interview
Q&A: Why Use GS piggyBac® Transposase Technology for Expression of Your Biotherapeutics?
Aspirin
Article
Tackling Complexity: From Molecule to Formulation
Whatever proves the best option, the talented Lonza team has the skills to identify it, and then...
micro image
Presentation (slides)
Optimizing GMP Manufacturing of Lipid Nanoparticles
Lonza is now offering next-generation encapsulation of nucleic acids with FDmiX. In this...
Article
Simplify the encapsulation process of nucleic acid payloads with FDmiX technology
Enable a reliable, swift scale-up to cGMP manufacturing for mRNA encapsulation with the high-end...
scientists working in lab
Article
Q&A: How to Maximise Cell Line Productivity and Efficiency
In this interview, Dr. Tabitha Bullock, a principal group leader at Lonza, tells us about some...